Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review of sequential immunotherapy strategies for alopecia areata suggests that combining initial intensive immunosuppression with maintenance therapy may effectively manage disease progression by modulating inflammation and restoring immune tolerance.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study concludes that combining chemotherapy with immune checkpoint inhibitors is additive rather than synergistic in terms of adverse events for advanced non-small cell lung cancer patients.

Targeted immunotherapy could be a promising new treatment for hair regrowth.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.